Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; 5 of the 31 sources its claims cite were checked for support.
Abstract
Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5-30 days after a "challenge" dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08-0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59-1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82-1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.
Overview
CoChat Summary
TL;DR
Systematic review and meta-analysis of poliovirus challenge studies found that OPV strongly reduces fecal poliovirus shedding after challenge, whereas IPV alone or added to OPV does not significantly reduce the prevalence of shedding. IPV may reduce the quantity and duration of virus shed, but evidence for nasopharyngeal mucosal protection was insufficient.
Key findings
- OPV-vaccinated individuals were protected against poliovirus shedding in stool after challenge compared with unvaccinated individuals: summary OR 0.13 (95% CI 0.08–0.24).
- IPV provided no significant protection against stool shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when added to OPV compared with OPV alone (summary OR 1.14 [95% CI 0.82–1.58]).
- Direct comparison of OPV versus IPV schedules favored OPV: overall OR 0.15 (95% CI 0.08–0.27).
- Five studies quantifying shedding found a 63%–91% (absolute 0.43–1.0 log10) reduction in mean quantity of poliovirus shed in stool among IPV-vaccinated compared with unvaccinated children; two of three studies examining duration found shorter shedding, and one study suggested combined quantity and duration reductions could reduce total virus shed by approximately 95%.
- There were insufficient studies of nasopharyngeal shedding to draw a conclusion.
Methods
- Systematic review of studies published through May 2011 identified via PubMed and Web of Knowledge, plus citation searching; 1,981 articles plus 6 additional studies were screened, yielding 31 stool-shedding studies and 4 nasopharyngeal-shedding studies meeting inclusion criteria.
- Inclusion required recording prevalence of vaccine poliovirus shedding in stool or nasopharyngeal samples collected 5–30 days after a challenge dose of live-attenuated poliovirus; exclusions included duplicate findings, immunocompromised individuals, fewer than 30 individuals, insufficient serotype/schedule/shedding data, or challenge more than 5 years after vaccination.
- Meta-analysis compared odds of shedding across vaccination categories—unvaccinated, trivalent OPV only, IPV only, and combined schedules—using fixed- or random-effects models according to heterogeneity, implemented in R with the rmeta package.
Limitations
- The paper states there were insufficient nasopharyngeal shedding studies to draw conclusions, and that few samples were positive with insufficient power to compare vaccination histories.
- The paper reports significant heterogeneity in some meta-analyses from variable sample timing, number/timing of vaccine doses, laboratory procedures, and unmeasured factors such as enteric infections; there were insufficient studies for a formal meta-regression.
- The paper states there are no studies with adequate control populations investigating IPV impact on wild-type poliovirus transmission in areas with efficient fecal-oral transmission, and that challenge with high-titer Sabin poliovirus differs from natural wild-type exposure; the relationship between quantity shed and onward transmission is unknown.
- Evident from the text: only 18 studies were included in the meta-analyses comparing vaccination histories, and only one study compared serotype 2 shedding in OPV-only versus OPV/IPV individuals, so no summary OR was calculated for that comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Flow diagram showing included studies according to PRISMA guidelines [46]. The number of published articles identified by the given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.](https://figures.cochat.ai/paper-figures/f7fa06a7c24446bdb28e75ad429edb87/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-1.jpg)
![Figure 2 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with unvaccinated individuals. Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The χ2 test for heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, <0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/cdf5934daf6143bea94adeadb60a35a7/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-2.jpg)
![Figure 3 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with unvaccinated individuals. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11, 0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/02e3301e07954edd96d8e51b7d7826c2/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-3.jpg)
![Figure 4 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values<0.001, 0.79, and 0.01 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/02290bcc61df4f4bbcf19524c4472bc4/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-4.jpg)
![Figure 5 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV compared with individuals vaccinated with OPV only. Labeling as for Figure 2. The schedule indicates the number and type of OPV doses received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 [49]). The χ2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).](https://figures.cochat.ai/paper-figures/f9e2423eecde4ebba5d508acc77f6bb4/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-5.jpg)
Verification
Claims the paper makes
4 Valid · 1 Not valid · 19 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response [7].”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Disputedcites [7] TM Herremans, 1999, Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus., J Immunol sourceExperimental — accuracy not yet measured
The Discussion says salivary IgG in IPV recipients was low or absent, suggesting it does not protect against mucosal poliovirus infection; any protective effect of circulating IgG remains untested. It instead attributes previously reported mucosal responses after IPV to prior priming with live virus and reports mucosal IgA responses after IPV boosting in previously OPV-vaccinated people. The proposed IgG-over-IgA explanation runs contrary to that account. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent evidence from India for waning intestinal immunity to poliovirus within a year of vaccination with OPV [38] and identification of wild-type polioviruses in stool samples from OPV immunized children [39] has generated interest in the potential for IPV to boost intestinal immunity among these children.”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Supportedcites [39] NC Grassly, 2010, Asymptomatic wild poliovirus infection in India among children previously immunized with oral poliovirus vaccine., J Infect Dis source
The Discussion reports that serotype 1 wild-type poliovirus was isolated from stool samples of children who reported receiving at least 10 OPV doses. This directly supports the identification attributed to this paper. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Five studies that quantified poliovirus shedding found a 63%–91% (or an absolute 0.43–1.0 log10) reduction in the mean quantity of poliovirus shed in stool samples collected from IPV vaccinated compared with unvaccinated children [5], [17]–[20] (Table S1).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Supportedcites [5] JL Henry, 1966, A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine., J Hyg (Lond) source
The ‘Amount of virus excreted after challenge’ section calculates mean virus content in feces and reports lower excretion in the killed-poliovaccine group than in the unvaccinated comparison group. This supports citing the paper as one of the five studies; the 63%–91% range describes the five studies collectively, not a result attributed to this paper alone. (LLM, conf=0.85)
- Not matchedcites [17]–[20]
A range of references, not one source.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The superior impact of OPV on intestinal mucosal immunity is confirmed by the meta-analysis of studies that directly compared schedules that exclusively used OPV or IPV (overall OR for OPV compared with IPV immunized children was 0.15 [0.08–0.27]).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, the prevalence of challenge poliovirus shedding was highly variable among studies, even for those that examined very similar vaccination schedules (Table S1).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 49 claims and to verify the 3 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IPV does not induce sufficient intestinal immunity to be effective in the prevention of virus spread [63,67].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“OPV vaccination is effective in preventing the shedding of WPV in the stool after exposure, which suggests that OPV induces sufficient intestinal mucosal immunity against PV infection and helps in the prevention of virus transmission [63].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [63]
Experimental — accuracy not yet measured
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Flow diagram showing included studies according to PRISMA guidelines”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Summary ORs and 95% confidence intervals were calculated on a log scale assuming either fixed effects or normally distributed random effects among studies according to the results of the x(2) test [44].”
MethodWang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Ogra, P. L., Karzon, D. T., Righthand, F., & MacGillivray, M. (1968) · New England Journal of Medicine · doi:10.1056/nejm196810242791701 · Cited by 397 · cited 2×
“In contrast, intramuscular injection of IPV induces serum antibodies but does not induce secretory IgA at the mucosal surfaces [3] and has a much more limited impact on the resistance of the intestine to infection [5].”
BackgroundBONE MARROW TRANSPLANTATION IN FIVE CHILDREN WITH SICKLE CELL ANAEMIA
Vermylen, C., Ninane, J., Fernandez Robles, E., & Cornu, G. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92239-8 · Cited by 196
Hovi, T., Huovilainen, A., Kuronen, T., Pöyry, T., Salama, N., Cantell, K., Kinnunen, E., Lapinleimu, K., Roivainen, M., Stenvik, M., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91566-7 · Cited by 186 · cited 1×
“Where importations of wild-type polioviruses to these countries have been documented, they have resulted in outbreaks ranging from a single case to over 100 cases of poliomyelitis [29–32].”
Background
Research works printed but not linked: 1
- G Enders-Ruckle, 1961, [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]., Dtsch Med Wochenschr, 86, 1999
Cited by
Items 101–200 of 221
Polio endgame: Lessons for the global rotavirus vaccination program
Jiang, B., Patel, M. M., & Glass, R. I. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.023 · Cited by 19
Puligedda, R. D., Vigdorovich, V. I., Kouiavskaia, D. V., Kattala, C. D., Zhao, J., Al‐Saleem, F. H., Chumakov, K., Sather, D. N., & Dessain, S. K. (2020) · Antibodies · doi:10.3390/antib9010005 · Cited by 20
“As a result, cVDPVs can infect the intestines of IPV-immune individuals, be shed in the stool, and pass asymptomatically through IPV-immune populations [2,3].”
BackgroundHarnessing mucosal immunity for protective vaccines
Kwon, D.-I., Bhagchandani, S. H., Ehrenzeller, S. A., & Iwasaki, A. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01273-7 · Cited by 27
“However, OPV, but not IPV, prevents faecal shedding in human poliovirus challenge studies 163 , underscoring the potential of mucosal vaccination to limit infection within the gut mucosa.”
Mucosal immunity and the eradication of polio
Donlan, A. N., & Petri, W. A. (2020) · Science · doi:10.1126/science.abb8588 · Cited by 18
Taniuchi, M., Begum, S., Uddin, M. J., Platts-Mills, J. A., Liu, J., Kirkpatrick, B. D., Chowdhury, A. H., Jamil, K. M., Haque, R., Petri, W. A., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02406-14 · Cited by 16
“Measurement of poliovirus in stool samples can thus be useful in evaluating mucosal immunogenicity (4), in estimating the transmission intensities of vaccine-derived virus, and for surveillance after polio eradication (5).”
BackgroundMarker of coxsackievirus‐B4 infection in saliva of patients with type 1 diabetes
Badia‐Boungou, F., Sané, F., Alidjinou, E. K., Ternois, M., Opoko, P. A., Haddad, J., Stuckens, C., Lefèvre, C., Gueorguieva, I., Hamzé, M., et al. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2916 · Cited by 18
“ity of saliva was implemented to determine the level of mucosal immunity against poliovirus.(30) It has been reported that this activity was due to specific secretory IgA.”
BackgroundVaccines against Bacterial Enteric Infections
Holmgren, J. R., & Levine, M. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00056-2 · Cited by 18
Yang, O. O., Ibarrondo, F. J., Price, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088621 · Cited by 15
“Oral polio vaccine (live attenuated) generates gut mucosal immunity that limits subsequent shedding of poliovirus after infection, while shedding in stool is noted after vaccination via deltoid intramuscular injection (inactivated), although both vaccines prevent systemic dissemination and poliomyelitis [8].”
BackgroundMcCarthy, K. A., Chabot‐Couture, G., & Shuaib, F. M. B. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1817-3 · Cited by 15
“However, the probability of reinfection is strongly reduced after a successful infection or vaccination; the metastudy presented in [11] estimates that the relative odds of shedding serotype 1 poliovirus post-challenge among OPV-vaccinated individuals compared with unvaccinated individuals is 0.”
BackgroundIntranasal and sublingual delivery of inactivated polio vaccine
Kraan, H., Soema, P. C., Amorij, J., & Kersten, G. F. A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.090 · Cited by 19
“immunity in the gut is a powerful mechanism for protection and interruption of polio transmission [9].”
BackgroundPan, W., Seidman, J. C., Ali, A., Hoest, C., Mason, C. J., Mondal, D., Knobler, S. L., & Bessong, P. O. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.080 · Cited by 15
Achieving and Maintaining Polio Eradication — New Strategies
Modlin, J. F., & Wenger, J. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1407783 · Cited by 15
Vaccine preventable viral diseases and risks associated with waterborne transmission
Ruggeri, F. M., & Fiore, L. (2012) · Annali dell Istituto Superiore di Sanità · doi:10.4415/ann_12_04_12 · Cited by 14
COVID‐19, varying genetic resistance to viral disease and immune tolerance checkpoints
Goodnow, C. C. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12419 · Cited by 16
“The first-generation inactivated Salk vaccine did not protect against poliovirus infection and fecal–oral transmission but did confer resistance to viral infection of the central nervous system and paralyzing poliomyelitis.(36,37) This property of suppressing index clinical cases but not virus transmission has led to…”
BackgroundPoliopolis: Pushing Boundaries of Scientific Innovations for Disease Eradication
Damme, P. V., Coster, I. D., Bandyopadhyay, A. S., Suykens, L., Rüdelsheim, P., Neels, P., Oberste, M. S., Weldon, W. C., Clemens, R. L., & Revets, H. (2019) · Future Microbiology · doi:10.2217/fmb-2019-0196 · Cited by 15
Devaux, C. A., Pontarotti, P., Levasseur, A., Colson, P., & Raoult, D. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1284337 · Cited by 16
Bashorun, A. O., Kotei, L., Jawla, O., Jallow, A. F., Saidy, A. J., Kinteh, M.-A., Kujabi, A., Jobarteh, T., Kanu, F. J., Donkor, S. A., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00631-x · Cited by 15
“The immunogenicity endpoints were seroprotection rates (percentage of participants with a reciprocal SNA titre ≥8 [3log 2 ]), seroconversion rates (percentage of participants with a baseline reciprocal SNA titre 8 and a post-vaccination reciprocal SNA titre ≥8), rates of 4-fold titre rise…”
BackgroundBhaumik, S. K., Kulkarni, R. R., Weldon, W. C., Silveira, E. L. V., Ahmed, H., Gunisetty, S., Chandele, A., Antia, R., Verma, H., Sutter, R. W., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy634 · Cited by 13
Tagbo, B. N., Ughasoro, M. D., & Esangbedo, D. O. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.053 · Cited by 13
Li, R., Li, C., Wang, H., Luo, H., Li, Y., Wang, J., Ying, Z., Yu, W., Shu, J. D., Wen, N., et al. (2015) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piv017 · Cited by 13
“duces strong intestinal mucosal immunity [8, 9].”
Bandyopadhyay, A. S., Asturias, E. J., O’Ryan, M., Oberste, M. S., Weldon, W. C., Clemens, R. L., Rüttimann, R. W., Modlin, J. F., & Gast, C. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.006 · Cited by 13
Alternative administration routes and delivery technologies for polio vaccines
Kraan, H., van der Stel, W., Kersten, G. F. A., & Amorij, J. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1158650 · Cited by 12
“The mucosal sIgA confers protection from poliovirus entry and multiplication in the intestine [52].”
BackgroundAltamirano, J., Purington, N., Behl, R., Sarnquist, C., Holubar, M. K., García‐García, L., Ferreyra-Reyes, L. D., Montero-Campos, R., Cruz‐Hervert, L. P., Boyle, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy650 · Cited by 13
“This is particularly reassuring for the children ≤5 years old with transmission in these communities, who are all primarily IPV-vaccinated, because IPV has been shown to confer inferior mucosal immunity, compared with OPV [28, 29].”
BackgroundNeonatal vitamin A supplementation and immune responses to oral polio vaccine in Zimbabwean infants
Church, J. A., Rukobo, S., Govha, M., et al. (2018) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/try126 · Cited by 12
Heinimäki, S., Malm, M., Vesikari, T., & Blazevic, V. (2018) · Journal of Immunology Research · doi:10.1155/2018/3487095 · Cited by 12
“Similarly, parenterally delivered inactivated polio vaccine (IPV) generates protective serum antibodies but not local intestinal mucosal antibodies in the gut, therefore being sufficient to protect against disease but insufficient to prevent wild poliovirus from replicating in intestines and spreading to the environme…”
BackgroundCost-effectiveness of norovirus vaccination in children in Peru
Mirelman, A. J., Ballard, S.-B., Saito, M., Kosek, M. N., & Gilman, R. H. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.004 · Cited by 11
“As demonstrated by the mucosal immunity and decrease in shedding of virus after oral poliovirus immunization relative to inactivated poliovirus immunization, the indirect vaccine benefits attributable to mucosal and herd immunity may be greater if a candidate NV vaccine is oral or intranasal rather than injectable [30…”
BackgroundFu, R., Altamirano, J., Sarnquist, C., Maldonado, Y., & Andrews, J. R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy605 · Cited by 10
Oral rotavirus vaccine shedding as a marker of mucosal immunity
Lee, B., Kader, M. A., Colgate, E. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01288-1 · Cited by 11
“Only 9 qPCR-positive specimens (25%) were also positive by stool RVA antigen enzyme immunoassay (EIA), of which 8 were Rotarix vaccine strain and 1 wild-type P[8] strain, indicating very low quantities of viral replication and shedding in this cohort.”
BackgroundResultInfluentialBrickley, E. B., Connor, R. I., Wieland‐Alter, W., Weiner, J. A., Ackerman, M. E., Arita, M., Gast, C., Coster, I. D., Damme, P. V., Bandyopadhyay, A. S., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa783 · Cited by 10
“series using only IPV induce negligible intestinal mucosal immunity to poliovirus [2, 3], and replication of Sabin OPV virus is not limited upon subsequent challenge [12].”
MethodMychaleckyj, J. C., Haque, R., Carmolli, M. P., Zhang, D., Colgate, E. R., Nayak, U., Taniuchi, M., Dickson, D. M., Weldon, W. C., Oberste, M. S., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.046 · Cited by 11
Sané, F., Bertin, A., Sioofy‐Khojine, A., Oikarinen, S., Alidjinou, E. K., Veijola, R., Toppari, J., Ilonen, J., Knip, M., Engelmann, I., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3305 · Cited by 10
“The neutralization assay provides a reflection of the activity of biological samples due to neutralizing antibodies against the challenging virus.(22,23) A neutralizing activity is observed soon after the infec-”
BackgroundPolio Eradication: Status, Struggles and Strategies
Bandyopadhyay, A. S., Burke, R. M., & Hawes, K. M. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004330 · Cited by 8
Giri, S., Kumar, N., Dhanapal, P., Venkatesan, J., Kasirajan, A., Iturriza‐Gómara, M., John, J. K., Abraham, A. M., Grassly, N. C., & Kang, G. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix687 · Cited by 9
“1398 • JID 2018:217 (1 May) • BRIEF REPORT has previously been shown in several studies of OPV recipients mainly from high-income countries [3].”
BackgroundSelf-citationWijayalath, W., Majji, S., Kleschenko, Y., Sang, L. P., Brumeanu, T., Villasante, E. F., Vasta, G. R., Fernández-Robledo, J.-A., & Casares, S. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087435 · Cited by 11
“to pathogens that do not enter through the oral route [60].”
BackgroundThe synergy of recombinant NSP4 and VP4 from porcine rotavirus elicited a strong mucosal response
Li, S., Tang, X., Zhou, J., et al. (2024) · Virology · doi:10.1016/j.virol.2024.110130 · Cited by 8
Recent Trends in Microneedle Development & Applications in Medicine and Cosmetics (2013–2018)
Kochhar, J. S., Tan, J., Kwang, Y. C., & Kang, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-15444-8_7 · Cited by 8
Moussa, S., Jenabian, M.-A., Gody, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063408 · Cited by 8
“Acquired intestinal immunity against viral antigens in children has been extensively described with other infections than HIV, for example after natural intestinal infections by rotavirus [97] or norovirus [98], or immunization with oral live attenuated or inactivated poliovirus vaccine [99,100].”
BackgroundEffective case/infection ratio of poliomyelitis in vaccinated populations
BENCSKÓ, G., & Ferenci, T. (2016) · Epidemiology and Infection · doi:10.1017/s0950268816000078 · Cited by 9
“From a recent review [19] we can deduce VE inf = 0·87 and VE inf = 0·19 (by subtracting the odds ratios against shedding presented there from 1).”
BackgroundHassan, J., Wangai, L. N., Borus, P., Khayeka‐Wandabwa, C., Karani, L. W., Kithinji, M., & Kiptoo, M. K. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2843-y · Cited by 10
Resik, S., Tejeda, A., Mach, O., Fonseca, M. C., Díaz, M., Alemañy, N., Hung, L. H., Alemán, Y., Mesa, I., Garcia, G., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy604 · Cited by 8
“Mucosal immunity was defined as a resistance to the excretion of poliovirus after the tOPV challenge [20].”
BackgroundWang, Y., Xu, Q., Jeyaseelan, V., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100133 · Cited by 8
Godin, A., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Ackerman, M. E., Weiner, J. A., Modlin, J. F., Arita, M., Bandyopadhyay, A. S., Gast, C., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.101028 · Cited by 7
Polio’s detection in London is a wake-up call
Grassly, N. C. (2022) · BMJ · doi:10.1136/bmj.o1589 · Cited by 8
Self-citationImmunomodulation by Enteric Viruses
Bernard, L., & Cadwell, K. (2023) · Annual Review of Virology · doi:10.1146/annurev-virology-111821-112317 · Cited by 10
Inactivated Polio Vaccine: its proposed role in the final stages of polio eradication
Davis, R., & Biellik, R. (2013) · Pan African Medical Journal · doi:10.11604/pamj.2013.14.102.2580 · Cited by 8
“A recent review [10] drew the following conclusions about the relative suitability of IPV and OPV for stopping WPV transmission in areas with poor sanitation.”
BackgroundVoorman, A., Habib, M. A., Hussain, I., Safdar, R. M., Ahmed, J., Weldon, W. C., Ahmed, I., Umer, M. A., Partridge, J., & Soofi, S. B. (2020) · Vaccine X · doi:10.1016/j.jvacx.2020.100067 · Cited by 8
“IPV can also limit pharyngeal shedding, which is believed to be a minor contributor to transmission [11].”
BackgroundWanke, A. T., & Bruns, F. (2022) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-022-03538-7 · Cited by 6
Mwamba, G. N., Nzaji, M. K., Hoff, N. A., et al. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s437351 · Cited by 6
“47 50–55 Vitamin A has a beneficial effect on immunogenicity especially since it has been proven to increase the number of cytokines and helper T cells.”
BackgroundLi, J., Zhang, Z., Zhang, H., Li, M., Li, X., Lu, L., Huang, F., & Wu, J. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1778409 · Cited by 6
Overcoming challenges en route to polio eradication
O’Leary, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01880-3 · Cited by 6
Snider, C. J., Zaman, K., Wilkinson, A. L., Aziz, A. B., Yunus, M., Haque, W., Jones, K. A. V., Wei, L., Estívariz, C. F., Konopka‐Anstadt, J. L., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.055 · Cited by 6
Habib, M. A., Soofi, S. B., Hussain, I., Ahmed, I., Hussain, Z., Tahir, R., Anwar, S., Cousens, S., & Bhutta, Z. A. (2023) · Vaccines · doi:10.3390/vaccines11091444 · Cited by 5
Evolution of Inactivated Poliovirus Vaccine Use for the Endgame and Beyond
Bandyopadhyay, A. S., & Orenstein, W. A. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz300 · Cited by 6
“Thus, IPV-only recipients, irrespective of primary schedule and doses, excrete the vaccine virus following an oral challenge in almost the same manner as those who are unvaccinated, with a marginal impact on reduction of duration and titer of virus shedding [9, 13, 14].”
Ding, K., Shang, K., Yu, Z., et al. (2018) · Journal of Veterinary Science · doi:10.4142/jvs.2018.19.2.232 · Cited by 6
“The sIgA antibody is the first line of defense against microbial infection, and it is the primary antibody mediating mucosal immunity [14,15].”
Backgroundvan Hoorebeke, C., Huang, C., Leary, S., Holubar, M. K., Altamirano, J., Halpern, M. S., Sommer, M. H., & Maldonado, Y. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy648 · Cited by 5
“The current literature shows a varied range for the proportion of positive samples collected from populations challenged with OPV [18].”
BackgroundGlobal Polio Eradication: Progress and Challenges
Bandyopadhyay, A. S., & Macklin, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-71165-8_30 · Cited by 8
Maximising the impact of inactivated polio vaccines
Brickley, E. B., & Wright, P. F. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30236-0 · Cited by 6
Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
Zhao, T., Li, J., Shi, H., Ye, H., Ma, R., Fu, Y., Liu, X., Li, G., Yang, X., Zhao, Z., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1911213 · Cited by 7
“In fact, the proportion of shedders among IPV-vaccinated individuals who receive OPV is similar to that among previously non-vaccinated OPV recipients.(8) Unlike those vaccinated with the trivalent (t)OPV vaccination schedule, recipients of the new immunization strategy are not vaccinated with live attenuated PV2 vacc…”
ResultSequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
Ciapponi, A., Bardach, A., Ares, L. R., Glujovsky, D., Cafferata, M. L., Romano, M., Cesaroni, S., & Aikant, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011260 · Cited by 5
Genetic Variants and Protective Immunity against SARS-CoV-2
Rabaan, A. A., Mutair, A. S. A., Aljeldah, M. M., Shammari, B. R. A., Sulaiman, T., Alshukairi, A. N., Alfaresi, M. S., Al-Jishi, J. M., Bati, N. A. A., Al-Mozaini, M., et al. (2022) · Genes · doi:10.3390/genes13122355 · Cited by 5
Kanungo, S., Kim, D. R., Haldar, B., Snider, C. J., Nalavade, U. P., Kim, S. A., Park, J., Sinha, A., Mallick, A. H., Manna, B., et al. (2017) · Heliyon · doi:10.1016/j.heliyon.2016.e00223 · Cited by 5
“Vaccination with only IPV was apparently inferior as measured by fecal shedding after challenge, but reportedly had different outcome when administered subsequent to doses of OPV [13, 14, 15].”
Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants
Church, J. A., Rukobo, S., Govha, M., Carmolli, M. P., Diehl, S. A., Chasekwa, B., Ntozini, R., Mutasa, K., Humphrey, J. H., Kirkpatrick, B. D., et al. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1359454 · Cited by 5
Kunishima, Y., Senpuku, K., Kataoka-Nakamura, C., Hirai, T., & Yoshioka, Y. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102731 · Cited by 4
“19 However, vaccine strain-derived poliomyelitis is considered a problem due to genetic reversion.”
Seo, G., Mandes, R., Wright, N. D., Hawkins, J. P., Landgraff, A., Lidder, R., Mohammed, U., Mangat, C. S., Michel, A.-S., Fafard, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92912-x · Cited by 6
“Overall, the time required to obtain a result from cell culture can have important consequences for the public health response because poliovirus can infect and shed from asymptomatic vaccinated and unvaccinated individuals 36 .”
The polio endgame: rationale behind the change in immunisation
Garon, J. R., & Patel, M. M. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311171 · Cited by 5
Zhang, Y., Liu, J., Li, H., Yuan, F., Jiang, C., Cang, T., Li, K., Hu, Q., Liu, J., & Zheng, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28806 · Cited by 4
Saleem, A. F., Kazi, Z., Zehra, M., Parkar, S., Macklin, G., Sifontes, G., Mainou, B. A., Alam, M., Cavestany, R. L., & Mach, O. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae006 · Cited by 4
Wu, Y., Wenyong, Z., Liu, Z., Jingxia, G., Lei, M., Shengjie, O., Zhang, B., Xiaohu, D., Wei-dong, L., & Guoyang, L. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25514 · Cited by 4
“The IPV does not replicate and is safer than the OPV; however, the IPV activates innate responses only at their site of injection.(5,6) Although the acquisition of immunity to polio vaccination is an important role, the accurate molecular pathways and functional networks are still a challenge.”
BackgroundPauly, M., Black, A. P., Khampanisong, P., Nouanthong, P., Hübschen, J. M., Nanthavong, N., Sayasinh, K., Jutavijittum, P., Samountry, B., Xeuatvongsa, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197370 · Cited by 4
Hussain, I., Umer, M. A., Khan, A., Sajid, M., Ahmed, I., Begum, K., Iqbal, J., Alam, M. M., Safdar, R. M., Baig, S., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1384410 · Cited by 3
Fu, Y., Ma, R., Zhao, Z., Mo, Z., Ying, Z., Li, J., Ye, H., Li, G., Liu, X., Liang, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01134-9 · Cited by 6
“However, IPV has been shown to induce only limited primary intestinal immunity and does not effectively halt viral replication upon subsequent exposure to either the vaccine virus or through fecal-oral transmission of poliovirus 15,16 .”
Addressing the Re-emergence of Poliovirus
Tripp, R. A. (2014) · Journal of Antivirals & Antiretrovirals · doi:10.4172/jaa.1000e116 · Cited by 3
“It is well known that IPV provides robust humoral immunity, but poorer mucosal immunity in the gut suggesting that IPV-vaccines might still shed the virus in feces [16-19].”
BackgroundManukyan, H., Tritama, E., Wahid, R., Konopka‐Anstadt, J. L., Konz, J., Chumakov, K., & Laassri, M. (2023) · Vaccines · doi:10.3390/vaccines11111729 · Cited by 3
“IPV, although effective at preventing poliovirus disease in recipients, is known to stimulate suboptimal mucosal immunity that does not prevent poliovirus transmission [6,7].”
BackgroundPoliovirus Vaccine—Inactivated
Vidor, E. J., & Modlin, J. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00049-9 · Cited by 5
Godin, A., Connor, R. I., Degefu, H. N., Rosato, P. C., Wieland‐Alter, W., Axelrod, K. S., Kovacikova, G., Weiner, J. A., Ackerman, M. E., Chen, E. Y., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae264 · Cited by 2
“Existing research on mucosal immunity to PVs has predominantly focused on intestinal immunity, measured in stool samples as PV type-specific neutralizing activity and immunoglobulin (Ig) A (reviewed in [4, 5]).”
Saleem, A. F., Jeyaseelan, V., Kazi, Z., Zehra, M., Alam, M. M., Macklin, G., Cavestany, R. L., Muhammad, S., Rehman, N. U., & Mach, O. (2025) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2025.100531 · Cited by 1
Snyder, J. P., Slavik, M. A., Harvey, P., del Río, R., Mainou, B. A., Sette, A., Kirkpatrick, B. D., Grifoni, A., & Crothers, J. W. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110607 · Cited by 3
Tesfaye, B., Chia, J. E., Nomhwange, T., Owuor, D. C., Muluh, T. J., Nosheen, S., Wakem, A. Y. D., Jimoh, A., Saatcioglu, A., Touray, K., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100752 · Cited by 2
Troy, S. B., & Maldonado, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00235-8 · Cited by 2
Mercer, L. D., Seña, A. C., Colgate, E. R., Crothers, J. W., Wright, P. F., Al-Ibrahim, M. S., Tritama, E., Vincent, A., Mainou, B. A., Zhang, Y., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00285-3 · Cited by 2
“20 Furthermore, reduced vaccine shedding following the second dose in OPV participants indicates successful induction of intestinal immunity, which is crucial to halt transmission in outbreak settings.”
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
Godin, A., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Weiner, J. A., Ackerman, M. E., Modlin, J. F., Sajjad, O. M., Arita, M., Gast, C., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf484 · Cited by 2
“Similarly, differences in responses across the serotypes have been shown, particularly to type 3 after a single dose of trivalent OPV [23], and our results are not generalizable to potential concomitant use with other polio vaccines (eg, bi-valent OPV [bOPV] birth doses).”
The Need and Potential of Inactivated Poliovirus Vaccine.
Garon, J. R., Orenstein, W. A., & John, T. J. (2016) · PubMed · Cited by 2
High population immunity reduces poliovirus community transmission
Garon, J. R., Sutter, R. W., & Orenstein, W. A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30417-6 · Cited by 2
Polio Today: State of the Global Eradication Program and Modern Strategy of WHO on Immunization
Ivanova, O. E. (2015) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2015-14-2-73-78 · Cited by 2
OPV Vaccination and Shedding Patterns in Mexican and US Children
Altamirano, J., Sarnquist, C., Behl, R., García‐García, L., Ferreyra-Reyes, L. D., Leary, S., & Maldonado, Y. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy636 · Cited by 2
“This decreased shedding duration indicates that there may be increased mucosal immunity against OPV [12, 14] and is likely the result of OPV exposure in the Mexican vaccinees that is absent among most of the US vaccinees.”
BackgroundHalpern, M. S., Altamirano, J., & Maldonado, Y. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy635 · Cited by 2
“Studies have demonstrated that IPV alone produces limited mucosal immunity to poliovirus [28, 29], which is also the case for HIV+ infants [20] whose OPV shedding is independent of the number of prior OPV doses administered.”
BackgroundEstívariz, C. F., Burns, C. C., & Macklin, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00050-5 · Cited by 4
Delpeyroux, F., & Colbère-Garapin, F. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu1139 · Cited by 3
“efficiently limiting viral transmission [10].”
Kawagishi, T., Sánchez-Tacuba, L., Feng, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.505917 · Cited by 2
Troy, S. B., & Maldonado, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00235-4 · Cited by 4
Oral and Fecal Polio Vaccine Excretion Following bOPV Vaccination Among Israeli Infants
Chorin, O., Markovich, M. P., Avramovich, E., Rahmani, S., Sofer, D., Weil, M., Shohat, T., Chorin, E., Tasher, D., & Somekh, E. (2022) · Vaccine · doi:10.1016/j.vaccine.2023.05.036 · Cited by 2
Snider, C. J., Zaman, K., Estívariz, C. F., Aziz, A. B., Yunus, M., Haque, W., Hendley, W. S., Weldon, W. C., Oberste, M. S., Pallansch, M. A., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126216 · Cited by 1
Rowland, T., Gopal, R., Patel, M., et al. (2025) · Eurosurveillance · doi:10.2807/1560-7917.es.2025.30.16.2500025 · Cited by 1
“Given the demographic of the cohort, it is probable most children would have received IPV and therefore could still become infected and spread poliovirus without exhibiting any symptoms, as IPV provides less protection against gastrointestinal replication of poliovirus [20].”
Parenteral Immunization and Protection from Mucosal Infection
Underdown, B. J., & Strober, W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00070-7 · Cited by 2
Complex task to estimate immune responses to various poliovirus vaccines and vaccination schedules
Zaman, K., & Anand, A. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30322-6 · Cited by 1
Yusuf, K. M., Ed, J., Yakubu, S., Ahmad, B., Nuhu, A., Iya, Z., & Yahaya, A. (2016) · Bayero Journal of Pure and Applied Sciences · doi:10.4314/bajopas.v8i2.4
“The major being the inability of mothers to recall the number of doses their children had received (Thomas and Nicholas, 2012).”
BackgroundKoloskova, О. К., Ivanova, L. A., & Marusyk, U. I. (2016) · ACTUAL INFECTOLOGY · doi:10.22141/2312-413x.4.09.2015.78822
Priming after Inactivated Poliovirus Vaccine: Implications for Polio Eradication
Sutter, R. W., Ensan, S., & Krishna, K. M. (2017) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000370
Bhutta, Z. A., Habib, M. A., & Soofi, S. B. (2017) · Oxford University Press eBooks · doi:10.1093/obo/9780199756797-0158
Metadata
- Authors
- Hird, T. R., & Grassly, N. C.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Grassly, Nicholas C.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e1002599
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3330118
- OpenAlex
- W1971110767
- Cited by
- 221
- References
- 55
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 22 · 2016: 18 · 2015: 20 · 2014: 21 · 2013: 11 · 2012: 2
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- inactivated poliovirus vaccine, oral polio vaccine, mucosal immunity, intestinal immunity, polio eradication, vaccine challenge, fecal-oral transmission, poliomyelitis control
- MeSH terms
- Animals, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Virus Shedding, Poliovirus, Immunity, Mucosal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.